Do you want to link to this External Website and leave Amgen.sa?

YOU ARE NOW LEAVING THIS WEBSITE.

Amgen Saudi Arabia takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Investors Relation Arabic Amgen Worldwide Web Resources Search

Amgen Worldwide

A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world.

Resources

Amgen has created a number of websites to better serve you with specific questions.

Scientific sources

Oncologie – Anti-tumor

Blincyto
BLINCYTO is used to treat adults with acute lymphoblastic leukaemia. BLINCYTO is used when acute lymphoblastic leukaemia has come back or has not responded to previous treatment (referred to as relapsed/refractory acute lymphoblastic leukaemia).

BLINCYTO is used to treat children (≥ 1 year old), teenagers and young adults with acute lymphoblastic leukaemia when previous treatments have not worked or have stopped working.

It is also used in patients with acute lymphoblastic leukaemia who still have a small number of cancer cells remaining after previous treatment (referred to as minimal residual disease).

Acute lymphoblastic leukaemia is a cancer of the blood in which a particular kind of white blood cell called “B-lymphocyte” is growing out of control.

The active ingredient in BLINCYTO is blinatumomab.

This belongs to a group of medicines called antineoplastic agents which target cancer cells.

This medicine works by enabling your immune system to attack and destroy these abnormal white blood cancer cells.

BLINCYTO is used when acute lymphoblastic leukaemia has come back or has not responded to previous treatment (referred to as relapsed/refractory acute lymphoblastic leukaemia).

It is also used in patients with acute lymphoblastic leukaemia who still have a small number of cancer cells remaining after previous treatment (referred to as minimal residual disease).

Imlygic
Imlygic is used to treat adult patients with a type of skin cancer called melanoma that has spread in the skin or to the lymph nodes, when surgery is not an option.

The active ingredient of Imlygic is talimogene laherparepvec. This is a weakened form of the cold sore virus.

Imlygic is used to treat adult patients with a type of skin cancer called melanoma that has spread in the skin or to the lymph nodes, when surgery is not an option.

The active ingredient of Imlygic is talimogene laherparepvec. This is a weakened form of herpes simplex virus type-1 (HSV-1), which is commonly called the cold sore virus.

To get Imlygic from HSV-1, the virus has been changed so that it multiplies more effectively in tumours than in normal cells.

This leads to destruction of infected tumour cells.Imlygic also works by helping your immune system to recognize and destroy tumours throughout your body.

Kyprolis
Kyprolis is used to treat adult patients with multiple myeloma who have had at least one previous treatment for this disease. Multiple myeloma is a cancer of plasma cells (a type of white blood cell).

Kyprolis is a medicine that contains the active substance carfilzomib.

Carfilzomib works by blocking the proteasome. The proteasome is a system within the cells that breaks down proteins when they are damaged or no longer needed.By preventing the breakdown of proteins in cancer cells, which are more likely to contain more abnormal proteins, Kyprolis causes the death of cancer cells.

Kyprolis is used to treat adult patients with multiple myeloma who have had at least one previous treatment for this disease.

Multiple myeloma is a cancer of plasma cells (a type of white blood cell).

Kyprolis will be given to you together with lenalidomide and dexamethasone, or only with dexamethasone. Lenalidomide and dexamethasone are other medicines used to treat multiple myeloma.

Vectibix
Vectibix is used in the treatment of metastatic colorectal cancer (cancer of the bowel) for adult patients with a certain type of tumor known as a “Wild-type RAS tumor”.

Kanjinti

A doctor may prescribe KANJINTI for certain types of breast and gastric cancer. KANJINTI contains the active ingredient trastuzumab.

KANJINTI contains the active ingredient trastuzumab, a monoclonal antibody. Monoclonal antibodies bind to specific proteins or antigens. Trastuzumab is designed to selectively bind to an antigen called human epidermal growth factor receptor 2 (HER2). HER2 is present in large numbers on the surface of some cancer cells, where it promotes their growth. When trastuzumab binds to HER2, it stops the growth of these cells, causing them to die.

Your doctor may prescribe KANJINTI for the treatment of breast and gastric cancer when:

  • You have early breast cancer, with high levels of a protein called HER2.
  • You have metastatic breast cancer (breast cancer that has spread beyond the original tumor) with high levels of HER2. KANJINTI may be prescribed in combination with chemotherapy medicines paclitaxel or docetaxel as the first treatment of metastatic breast cancer or it may be prescribed separately if other treatments prove ineffective. It is also used in combination with medicines called aromatase inhibitors, in patients with high levels of HER2 and hormone receptor positive metastatic breast cancer (cancer sensitive to the presence of female reproductive hormones).
  • You have metastatic gastric cancer with high levels of HER2 when used in combination with other medicines for the treatment of cancer, capecitabine or 5-fluorouracil and cisplatin.

Source: Patient information leaflets, Amgen. See www.ema.europa.eu for the most up-to-date versions.

Products

Our medicines

Amgen Biosimilars

Medical Information

Related Links

Oncology & Supportive-Therapy

Oncology – Anti-tumor

Cardiovascular disease

Hematology (blood)

Kidney disease

Osteoporosis

Inflammatory diseases